TrialBMJ open respiratory research2026

Developing low-carbon salbutamol MDI: assessment of relative bioavailability and pharmacodynamic relative potency of salbutamol MDI with propellant HFA-152a.

Sebastian Moreira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.